PREcision Medicine through IntErrogation of Rna in the kidnEy (PREMIERE)

摘要 肾脏已经形成了一个复杂的三维结构来服务于它的关键功能，包括 排泄废物，维持体内水盐平衡，血压 控制和荷尔蒙功能。了解个体肾细胞类型在这些过程中的作用 在健康和疾病方面，开发新的靶向疗法至关重要。由此引发的广泛研究 研究小组和其他人已经开始确定肾活检组织中的分子疾病机制 并帮助开发了新的疾病标志物和治疗方法。然而，到目前为止，这些研究都是 限制使用活组织匀浆，使其难以辨别细胞中激活的特定途径 类型。 肾问诊精准医学(首映)网将带来 来自三个具有不同、互补专业知识的领先生物医学研究机构的研究人员 在一起。我们的团队在共同开发最先进的方法方面有着既定的记录 在肾脏疾病的分子分析中。我们将着手挖掘我们现有的数以千计的 使用高级数据从肾活检组织中提取单细胞特征的基因表达谱 采矿工具。与此同时，我们将在我们的实验室中开发技术，以实现肾脏的单细胞分析。 并按比例缩小它们，这样他们就可以处理从小肾活检中提取的单个细胞。 这些单细胞图谱将与患者的疾病状态联系起来。与以下项关联的密钥签名 特定的细胞和疾病将被提取并定位在肾脏的三维环境中 在项目的第一阶段使用特定的RNA染色技术。在第二阶段，分析 战略将被扩大，以便从特定的患者群体中获得单细胞图谱 健壮和可重现的方式。 为此，首映调查人员将与纸巾采购网站和中央 KPMP的枢纽，利用他们在团队科学方面的20年经验，使在第一届KPMP结束时 资金周期新颖，细胞类型特定的治疗靶点被确定，以推动 未来。

ABSTRACT The kidney has developed a complex, three-dimensional architecture to serve its key functions, including excretion of waste substances, maintenance of the internal balance for fluid and salt, blood pressure control, and hormonal function. Understanding the roles of the individual renal cell types in these processes in health and disease is critical to develop novel targeted therapies. Extensive studies lead by this investigative group and others have started to identify molecular disease mechanism in renal biopsy tissues and helped to develop novel disease markers and therapies. However, up to now these studies were limited using biopsy tissue homogenates, making it difficult to discern the specific pathways activated in cell types. The PREcision Medicine through IntErrogation of Rna in the kidnEy (PREMIERE) Network will bring investigators from three leading biomedical research institutions with diverse, complementary expertise together. Our team has an established track record in working jointly to develop state of the art approaches in molecular analysis of renal disease. We will set out to mine our existing compendium of thousands of gene expression profiles from renal biopsy tissues to extract single cell signatures using advanced data mining tools. In parallel we will develop technologies in our laboratories towards single cell analysis of renal tissues and scale them down so that they can work on single cells extracted from small renal biopsies. These single cell profiles will be linked to the disease states of the patients. Key signatures associated with specific cells and diseases will be extracted and localized in the three dimensional context of the kidney using specific RNA staining techniques in the first phase of the project. In the second phase, the analytical strategies will be scaled up so that single cell profiles from specific groups of patients can be obtained in a robust and reproducible manner. To this end the PREMIERE investigators will work closely with the tissue procurement sites and the Central Hub of the KPMP, using their 20 years of experience in team science, so that at the end of the first KPMP funding cycle novel, cell type specific treatment targets are identified fueling the therapeutic pipelines of the future.